BioHarvest Sciences (NASDAQ:BHST) Trading Down 5.5% – Here’s Why

Shares of BioHarvest Sciences Inc. (NASDAQ:BHST) fell 5.5% on Thursday . The company traded as low as $2.75 and last traded at $2.75. Approximately 36,352 shares were traded during trading, an increase of 61% from the average session volume of 22,582 shares. The stock had previously closed at $2.91.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, BioHarvest Sciences currently has an average rating of “Hold” and an average price target of $10.00.

BioHarvest Sciences Trading Down 5.5%

The company’s 50 day simple moving average is $3.76 and its 200-day simple moving average is $4.45. The firm has a market cap of $53.95 million, a P/E ratio of -4.66 and a beta of 0.70. The company has a quick ratio of 2.44, a current ratio of 2.96 and a debt-to-equity ratio of 0.03.

BioHarvest Sciences (NASDAQ:BHST) last released its earnings results on Thursday, May 14th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. BioHarvest Sciences had a negative return on equity of 76.03% and a negative net margin of 32.54%.The firm had revenue of $8.51 million for the quarter, compared to analysts’ expectations of $8.50 million. As a group, research analysts predict that BioHarvest Sciences Inc. will post -0.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioHarvest Sciences

Hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in BioHarvest Sciences in the fourth quarter worth $60,000. Geode Capital Management LLC purchased a new stake in shares of BioHarvest Sciences during the fourth quarter valued at $61,000. HRT Financial LP bought a new position in shares of BioHarvest Sciences in the fourth quarter worth about $75,000. Marshall Wace LLP bought a new position in shares of BioHarvest Sciences in the fourth quarter worth about $110,000. Finally, Silverberg Bernstein Capital Management LLC purchased a new position in BioHarvest Sciences in the 1st quarter worth about $113,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.